Literature DB >> 16281914

Co-expression/co-location of S100 proteins (S100B, S100A1 and S100A2) and protein kinase C (PKC-beta, -eta and -zeta) in a rat model of cerebral basilar artery vasospasm.

F Lefranc1, C Decaestecker, J Brotchi, C W Heizmann, O Dewitte, R Kiss, T Mijatovic.   

Abstract

OBJECT: The cellular events leading to cerebral vasospasm after subarachnoid haemorrhages (SAH) involve a number of members of the protein kinase C (PKC) family. However, whereas calcium is thought to play a number of major roles in the pathophysiology of SAH, a number of PKCs function independently of calcium. We recently emphasized the potential role of the calcium-binding S100 proteins in a 'double haemorrhage' rat model of SAH-induced vasospasm. A number of S100 proteins are known to interfere directly with PKC, or indirectly with PKC substrates. We therefore investigated whether specific S100 proteins and PKCs are co-expressed/co-located in a rat model of SAH-induced vasospasm. METHODS AND
RESULTS: SAH-induced vasospasm in rats (by means of a double cisternal injection of autologous blood from a rat femoral artery) distinctly modified the expression levels of calcium-dependent PKC-alpha and PKC-beta and calcium-independent PKC-eta and PKC-zeta in endothelial and smooth-muscle cells. The RNA levels of these four PKC isotypes were determined by quantitative RT-PCR. The present study reveals that, in endothelial cells, the S100B expression/location correlate well with those of PKC-eta, and those of S100A1 with PKC-beta. In smooth-muscle cells S100A2 expression/location correlate with those of PKC-eta, and those of S100B with PKC-zeta.
CONCLUSION: The present data argue in favour of a joint action of the S100 protein network and the PKC signalling pathway during cerebral vasospasm.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281914     DOI: 10.1111/j.1365-2990.2005.00682.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  7 in total

Review 1.  The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments.

Authors:  Peter Solár; Alemeh Zamani; Klaudia Lakatosová; Marek Joukal
Journal:  Fluids Barriers CNS       Date:  2022-04-11

Review 2.  S100A1: a multifaceted therapeutic target in cardiovascular disease.

Authors:  David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A Katus; Thomas G Parker; Patrick Most
Journal:  J Cardiovasc Transl Res       Date:  2010-07-20       Impact factor: 4.132

Review 3.  S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy.

Authors:  Carolin Kraus; David Rohde; Christian Weidenhammer; Gang Qiu; Sven T Pleger; Mirko Voelkers; Melanie Boerries; Andrew Remppis; Hugo A Katus; Patrick Most
Journal:  J Mol Cell Cardiol       Date:  2009-06-16       Impact factor: 5.000

4.  S100A1: Structure, Function, and Therapeutic Potential.

Authors:  Nathan T Wright; Brian R Cannon; Danna B Zimmer; David J Weber
Journal:  Curr Chem Biol       Date:  2009-05-01

5.  Inhibition of the Receptor for Advanced Glycation End-Products (RAGE) Attenuates Neuroinflammation While Sensitizing Cortical Neurons Towards Death in Experimental Subarachnoid Hemorrhage.

Authors:  Hua Li; Jia-Sheng Yu; Ding-Ding Zhang; Yi-Qing Yang; Li-Tian Huang; Zhuang Yu; Ru-Dong Chen; Hong-Kuan Yang; Chun-Hua Hang
Journal:  Mol Neurobiol       Date:  2016-01-15       Impact factor: 5.590

6.  Immunohistochemical detection of S100A1 in the postmortem diagnosis of acute myocardial infarction.

Authors:  Haitao Bi; Ying Yang; Jianye Huang; Yingmin Li; Chunling Ma; Bin Cong
Journal:  Diagn Pathol       Date:  2013-05-17       Impact factor: 2.644

Review 7.  Role of Damage Associated Molecular Pattern Molecules (DAMPs) in Aneurysmal Subarachnoid Hemorrhage (aSAH).

Authors:  Shafqat Rasul Chaudhry; Ahmad Hafez; Behnam Rezai Jahromi; Thomas Mehari Kinfe; Alf Lamprecht; Mika Niemelä; Sajjad Muhammad
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.